Abstract
A small-molecule inhibitor and drug screen identifies PARPi and ATRi as candidate therapies for DSRCT. A, Schematic illustration of the workflow of small-molecule inhibitor and drug screen performed on the JN1 cell line. B, Waterfall plot displaying the difference in AUC between the JN1 cell line (AUCJN1) and the panel of 92 cell lines used for comparison (AUCmedian) for the 79 evaluated small-molecule inhibitors or drugs. Red, PARPi; blue, ATRi; green, conventional cytotoxic. C–F, Dose–response survival curves of the DSRCT cell lines JN1 and R, and the A673 (Ewing sarcoma) and SaOS-2 (osteosarcoma) cell lines exposed to talazoparib (C), olaparib (D), M4344 (E), or AZD6738 (F) for 7 days. Mean ± SD; n = 3. G and H, Violin plots showing the relative sensitivity (log2-fold change of cell viability) of cell lines exposed to the PARPi talazoparib (G) or olaparib (H) after a single-dose exposure at 2.5 μmol/L for 5 days in the DepMap database (PRISM Repurposing 23Q2), in comparison with that of the JN1 and R cell lines. JN1 and R cell line sensitivities were extrapolated from the survival assays presented in C and E; SFs were calculated at 2.5 μmol/L and log2 transformed. Ewing sarcoma cell lines (n = 16): RDES, A673, SKES1, CADOES1, EWS502, MHHES1, EW8, A673STAG2KO16, A673STAG2KO45, A673STAG2NT14, A673STAG2NT23, CBAGPN, CHLA10, SKNEP1, SKPNDW, and TC32; osteosarcoma cell lines (n = 5): G292CLONEA141B1, MG63, U2OS, HOS, and SJSA1; soft-tissue sarcoma cell lines (n = 7): S117, TE617T, HT1080, HS729, RD, RKN, and RH30, including rhabdomyosarcoma (n = 4), leiomyosarcoma (n = 1), fibrosarcoma (n = 1), and NOS sarcoma cell lines (n = 1), respectively. The BRCA1/2-mutant IGROV1 ovarian cancer cell line and BRCA1-mutant MDA-MB-436 breast cancer cell line were used as positive controls for sensitivity to PARPi. **, P < 0.01; ****, P < 0.0001; ns, not significant.